The Endocannabinoid System May Suppress Neuroinflammation and Fight Tumors — A Review of the Mechanisms | Research

The takeaway

Cannabinoids' immunosuppressive properties — including inhibiting immune cell proliferation and reducing pro-inflammatory cytokines — may have therapeutic applications in autoimmune disorders and cancer.

Anyone interested in the science behind claims that cannabis affects the immune system or fights cancer.

What the researchers found

This review mapped the endocannabinoid system's relationship with the immune system and cancer biology. The key mechanisms included CB1 and CB2 receptor activation suppressing immune responses through multiple pathways: inhibiting white blood cell proliferation, triggering T cell apoptosis (programmed death), activating macrophages, and reducing pro-inflammatory cytokine secretion.

For neuroinflammatory autoimmune disorders like multiple sclerosis, these immunosuppressive properties pointed toward potential therapeutic use — dampening the overactive immune response that damages myelin. For cancer, the picture was more complex: cannabinoids showed anti-tumor properties in both in vitro (cell culture) and in vivo (animal) studies, including inhibiting tumor cell proliferation, inducing cancer cell death, and reducing tumor blood vessel formation.

The review compiled evidence from clinical trials alongside preclinical work, though it noted that the clinical evidence remained early-stage.

Why it matters

The endocannabinoid system sits at the intersection of neuroscience and immunology. This review showed that cannabinoids don't just affect mood and pain — they fundamentally modulate immune function. For conditions where the immune system attacks the body (autoimmune diseases) or fails to control abnormal growth (cancer), that modulation could theoretically be therapeutic.

But "could theoretically" is doing heavy lifting. The jump from "cannabinoids kill cancer cells in a dish" to "cannabis treats cancer in humans" is enormous, and this review was careful to note that clinical evidence remained limited.

The numbers in context

• Cannabinoid immunosuppressive effects: inhibited leukocyte proliferation, induced T cell apoptosis, activated macrophages

• Reduced pro-inflammatory cytokines via CB1 and CB2 activation

• Anti-tumor effects demonstrated in vitro and in vivo across multiple cancer types

• Clinical trial evidence still early-stage

How the study worked

Narrative review of preclinical and clinical literature on the endocannabinoid system's role in immune regulation, neuroinflammation, and cancer biology. Covers CB1 and CB2 receptor mechanisms, immune cell interactions, and anti-tumor effects across multiple cancer types.

Who was studied

Review of various studies on cannabinoids and autoimmune disorders, primarily in animal models.

What this study cannot tell us

Narrative review with no systematic methodology. Anti-tumor findings are largely preclinical — lab dishes and animal models. Clinical trial evidence for cancer treatment was limited and early-stage. The review covers broad territory without deep analysis of any single condition. Publication bias likely favors positive preclinical results.

How to read the evidence

Narrative review synthesizing preclinical and limited clinical evidence. Strong mechanistic framework but most therapeutic claims remain unproven in humans.

When this study was published

Published in 2021. Cannabinoid immunology and oncology research continue advancing but clinical applications remain early-stage.

The bigger picture

This review contributed to a growing body of literature exploring whether the endocannabinoid system's immune-modulating properties can be harnessed therapeutically. The anti-cancer angle attracts enormous public interest but also enormous potential for misinterpretation. Showing that cannabinoids affect cancer cells in a lab is very different from showing they treat cancer in people.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Can cannabinoid-based immunosuppression be targeted precisely enough for clinical use in autoimmune disorders?
Will the anti-tumor effects seen in preclinical models translate to meaningful clinical outcomes?
Could long-term immunosuppression from heavy cannabis use have unintended consequences?

Common questions

Can cannabis treat cancer?

Cannabinoids have shown anti-tumor effects in cell cultures and animal models — inhibiting growth and inducing cancer cell death. But clinical evidence in humans is still very early. Lab results often don't translate to real treatments.

Does cannabis suppress the immune system?

Yes, through CB1 and CB2 receptor mechanisms. This can theoretically help in autoimmune disorders where the immune system is overactive, but it could also be a concern for people who need robust immune function.

Read the original research

Therapeutic Attributes of Endocannabinoid System against Neuro-Inflammatory Autoimmune Disorders.

Molecules (Basel, Switzerland), 26(11)

Molecules is a peer-reviewed journal known for publishing research on chemistry and related fields.

View on PubMed ↗Publisher’s paper ↗

Citation

Ahmed, Ishtiaq; Rehman, Saif Ur; Shahmohamadnejad, Shiva; Zia, Muhammad Anjum; Ahmad, Muhammad; Saeed, Muhammad Muzammal; Akram, Zain; Iqbal, Hafiz M N; Liu, Qingyou. (2021). Therapeutic Attributes of Endocannabinoid System against Neuro-Inflammatory Autoimmune Disorders.. Molecules (Basel, Switzerland), 26(11). https://doi.org/10.3390/molecules26113389